Ganirelix

Summary

Ganirelix is a prescription GnRH‑antagonist peptide administered subcutaneously. It is approved for use in assisted reproductive technology to rapidly suppress the pituitary release of LH and FSH during controlled ovarian hyperstimulation, preventing an untimely LH surge. The drug’s quick onset and short protocol have also prompted investigation for hormone‑dependent cancers and other reproductive disorders.

Mechanism of Action

Ganirelix binds competitively to the gonadotropin‑releasing hormone receptor (GnRH‑R) on pituitary gonadotrophs, blocking endogenous GnRH from activating the receptor. This immediate blockade halts the pulsatile secretion of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), thereby preventing the LH surge that triggers ovulation. The effect is reversible once the drug is cleared, allowing controlled timing of ovulation in IVF cycles.

What the Research Shows

A 2006 Cochrane review of 27 randomised trials compared GnRH‑antagonist protocols (including ganirelix) with the long GnRH‑agonist protocol. Antagonist cycles showed a modestly lower clinical pregnancy odds (OR 0.84) but a significant reduction in severe ovarian hyperstimulation syndrome (RR 0.61) and lower gonadotropin requirements. A phase‑I pharmacokinetic study demonstrated that a 0.25 mg subcutaneous dose of ganirelix is >90% bioavailable, with a half‑life of ~12.8 h. A 2019 randomized trial in oocyte‑donor cycles found that ganirelix and oral medroxyprogesterone acetate yielded similar numbers of mature oocytes, confirming its efficacy in LH‑surge suppression. A 2024 review highlighted ongoing interest in GnRH antagonists for advanced prostate, ovarian and endometrial cancers, but clinical data remain early‑phase.

Reported Benefits

Ganirelix provides rapid, reversible suppression of LH/FSH without the initial hormonal flare seen with agonists, allowing a shorter stimulation schedule. Its high subcutaneous bioavailability (>90%) ensures reliable dosing. Clinical use reduces the incidence of severe OHSS and lowers total gonadotropin consumption, offering a safer and more convenient option for many IVF patients.

Limitations of the Evidence

Evidence indicates lower pregnancy rates compared with the traditional long GnRH‑agonist protocol, necessitating thorough counseling. Most data are confined to assisted reproduction; long‑term outcomes and efficacy in cancer therapy are still investigational. The drug’s benefit in reducing OHSS must be weighed against the modest reduction in overall pregnancy success.

Safety Considerations

Short‑term studies report ganirelix to be well tolerated, with few immediate adverse events. The main safety advantage is a lower risk of severe OHSS. Nonetheless, clinicians should monitor for hypo‑estrogenic symptoms and ensure appropriate timing of the trigger injection. Use in hormone‑sensitive malignancies remains experimental, and safety in those settings is not yet established.

How It Is Administered

Ganirelix is supplied as a subcutaneous injection, typically 0.25 mg daily beginning on stimulation day 5‑6 (or when the leading follicle reaches ~14 mm) and continued until hCG trigger. The formulation is an acetate salt with high aqueous solubility, allowing reliable absorption and a convenient dosing schedule.

Routes of Administration

Goals & Uses

• Reduction of ovarian hyperstimulation syndrome (OHSS) riskSafety In ARTModerate
• Prevent premature LH surgeReproductiveHigh
• Treatment of endometriosisGynecologyLow
• Controlled ovarian hyperstimulation for IVFAssisted Reproductive TechnologyHigh
• Prostate cancer (androgen deprivation)OncologyLow
• Prevention of premature LH surge during COHReproductive EndocrinologyHigh

Contraindications

• Severe renal or hepatic impairmentOrgan ImpairmentModerate
• Hypersensitivity to ganirelix or any component of the formulationAllergyHigh
• Hypersensitivity to ganirelix or any componentAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Known hypersensitivity to GnRH or GnRH analogsAllergyHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Hypersensitivity/anaphylaxisImmunologicalRare
• HeadacheNeurologicUncommonPain in the head or upper neck
• Abdominal pain/pelvic painGastrointestinal/reproductiveCommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Hot flushesVasomotorCommon
• Ovarian hyperstimulation syndrome (OHSS)ReproductiveUncommon

Drug Interactions

• Human Chorionic Gonadotropin (hCG)Low
• Gonadotropins (FSH, hMG)Low
• GnRH agonistsHigh

Population Constraints

• PregnancyReproductive SafetyAbsolute
• Hepatic impairmentOrgan FunctionRelative
• Renal impairmentOrgan ImpairmentRelative
• Women undergoing IVFReproductiveRelative
• Pediatric patientsAgeAbsolute
• Postmenopausal womenReproductive StatusAbsolute

Regulatory Status

• European UnionApprovedApproved: controlled ovarian stimulation in IVFAuthorized in member states.
• United StatesApprovedApproved: controlled ovarian stimulation in IVFMarketed as Orgalutran.
• United KingdomApprovedApproved: controlled ovarian stimulation in IVF

Approved in the US (FDA) and EU for use in IVF protocols; marketed under the brand name Orgalutran.

Evidence & Sources

• Gonadotrophin-releasing hormone antagonists for assisted conception
  Journal ArticleHighAl-Inany HG, Abou-Setta AM, Aboulghar M2006-01-01T00:00:00.000000Z
• LHRH antagonists
  Journal ArticleModerateHaviv F, et al.1998-01-01T00:00:00.000000Z
• Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
  Journal ArticleModerateOberyé JJ, et al.1999-01-01T00:00:00.000000Z
• GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy
  Journal ArticleModeratePatel S, et al.2024-01-01T00:00:00.000000Z
• Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial
  Journal ArticleModerateBeguería R, et al.2019-01-01T00:00:00.000000Z

Frequently Asked Questions